Abstract:Achieving selectivity across the human kinome is a major hurdle in kinase inhibitor drug discovery. Assays using active, phosphorylated protein kinases bias hits toward poorly selective inhibitors that bind within the highly conserved adenosine triphosphate (ATP) pocket. Targeting inactive (vs active) kinase conformations offers advantages in achieving selectivity because of their more diversified structures. Kinase cascade assays are typically initiated with target kinases in their unphosphorylated inactive forms, which are activated during the assays. Therefore, these assays are capable of identifying inhibitors that preferentially bind to the unphosphorylated form of the enzyme in addition to those that bind to the active form. We applied this cascade assay to the emerging cancer immunotherapy target hematopoietic progenitor kinase 1 (HPK1), a serine/threonine kinase that negatively regulates T cell receptor signaling. Using this approach, we discovered an allosteric, inactive conformation-selective triazolopyrimidinone HPK1 inhibitor, compound 1. Compound 1 binds to unphosphorylated HPK1 >24-fold more potently than active HPK1, is not competitive with ATP, and is highly selective against kinases critical for T cell signaling. Furthermore, compound 1 does not bind to the isolated HPK1 kinase domain alone but requires other domains. Together, these data indicate that 1 is an allosteric HPK1 inhibitor that attenuates kinase autophosphorylation by binding to a pocket consisting of residues within and outside of the kinase domain. Our study demonstrates that cascade assays can lead to the discovery of highly selective kinase inhibitors. The triazolopyrimidinone described in this study may represent a privileged chemical scaffold for further development of potent and selective HPK1 inhibitors.

Selective inhibition of the kinase DYRK1A by targeting its folding process

Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors

Selective inhibition reveals the regulatory function of DYRK2 in protein synthesis and calcium entry

An Isoform-Selective, Small-Molecule Inhibitor Targets the Autoregulatory Mechanism of p21-Activated Kinase

Discovery and Functional Characterization of a Potent, Selective, and Metabolically Stable PROTAC of the Protein Kinases DYRK1A and DYRK1B

Imidazo[1,2-b]pyridazines as inhibitors of DYRK kinases

Structural perspective on the design of selective DYRK1B inhibitors

Insights into Mechanism of Pyrido[2,3-D]pyrimidines As DYRK1A Inhibitors Based on Molecular Dynamic Simulations.

Discovering a novel dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitor and its impact on tau phosphorylation and amyloid-β formation

Selective Macrocyclic Inhibitors of DYRK1A/B.

Discovery of a novel DYRK1A inhibitor with neuroprotective activity by virtual screening and in vitro biological evaluation

Structure-kinetic relationship reveals the mechanism of selectivity of FAK inhibitors over PYK2

Selection of Peptide Inhibitors for Double-Stranded RNA-dependent Protein Kinase PKR

Controlling Kinase Activities by Selective Inhibition of Peptide Substrates

Dual-Action Kinase Inhibitors Influence p38α MAP Kinase Dephosphorylation

Kinase Inhibition via Small Molecule‐Induced Intramolecular Protein Cross‐Linking

Discovery of an Allosteric, Inactive Conformation-Selective Inhibitor of Full-Length HPK1 Utilizing a Kinase Cascade Assay

Dual-Action Kinase Inhibitors Control p38α MAP Kinase Threonine Dephosphorylation

Affimer-mediated Locking of P21-Activated Kinase 5 in an Intermediate Activation State Results in Kinase Inhibition.

Modulation of the substrate specificity of the kinase PDK1 by distinct conformations of the full-length protein

Small Molecules That Allosterically Inhibit P21-Activated Kinase Activity by Binding to the Regulatory P21-Binding Domain.